Ivy Rx vs Ro
Ro costs $26 less a month.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Ivy Rx
Best for: coverage in all 50 states, which most sellers will not confirm
Visit Ivy Rx →
Ro
Best for: knowing which pharmacy fills the vial: it names Roman Health Pharmacy LLC
Visit Ro →If you are choosing between Ivy Rx and Ro, the first difference is cost: Ro is $26 a month cheaper at the entry price. Ivy Rx leads our six-part score, 7.3 to 6.7.
Ivy Rx vs Ro price
Ro is the cheaper way in: $149 a month against $175 a month at Ivy Rx. That is $26 less each month (15% lower), or about $312 over a year of treatment.
Medications and formats
Ivy Rx and Ro do not overlap on medication; only Ivy Rx lists semaglutide and tirzepatide; only Ro lists orforglipron.
On format, Ivy Rx prices compounded injections, while Ro prices brand-name pens.
If you want the FDA-approved brand rather than a compounded version, Ro is the only one of the two with a brand-name price.
Where each one treats patients
Ivy Rx lists 50 states, and Ro does not publish where it ships.
Pricing
Ivy Rx
Range up to $197/mo
Range up to $297/mo
Ro
Additional membership fees apply
What each price covers
Both prices cover the clinician visit.
Ivy Rx's price also covers the medication itself and shipping, which Ro does not claim.
Ro's price also covers lab work and coaching, which Ivy Rx does not claim.
Ivy Rx is silent on lab work and coaching.
Ro is silent on shipping.
That matters most for the drug: unless Ro confirms otherwise, budget for medication on top of its listed price.
Ivy Rx
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Ro
Covered by the monthly price
Medication
Charged on top
Clinician visits
In the price
Shipping
Not stated
Lab work
In the price
Coaching
In the price
Where each one scores higher
Overall, Ivy Rx scores 7.3 and Ro 6.7 out of 10.
Ivy Rx is stronger on effectiveness (10.0 vs 8.0), accessibility (10.0 vs 5.0) and support (7.0 vs 5.5).
Ro is stronger on value (5.0 vs 3.0) and trust & safety (8.0 vs 7.5).
User experience is within half a point.
Ivy Rx
7.3/10
Ro
6.7/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
FDA warning letters
Neither Ivy Rx nor Ro has an FDA warning letter on record with us.
Features & Coverage
| Feature | Ivy Rx | Ro |
|---|---|---|
| Starting Price | $175/mo | ✓$149/mo |
| Features | 3 features | ✓7 features |
| States Available | 50 | Not disclosed |
| Compounded | ✓ Yes | — |
| Brand Name | — | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warning Letters | None | None |
About Ivy Rx
Ivy Rx is a telehealth seller running tiered compounded semaglutide and tirzepatide programs.
Read our full Ivy Rx review →About Ro
Foundayo (orforglipron), the new oral GLP-1 from Eli Lilly, joined Ro on April 9 2026 at $149/month for the lowest dose, membership on top. Beside it sit compounded semaglutide and the brand-name pair, Zepbound and Wegovy. No obesity care formulary in the category is more comprehensive. In the US, only a handful of direct-to-patient telehealth companies are larger.
Read our full Ro review →Pros & Cons
Ivy Rx
What we like
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price stays the same as your dose goes up
- The monthly price includes the medication, clinician visits and shipping
- Serves all 50 states
- We found no FDA warning letters issued to Ivy Rx
Watch-outs
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Ro
What we like
- Orforglipron costs $149 a month, close to the $149 median for brand-name orforglipron across the sellers we compare
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes clinician visits, lab work and coaching
- Names Roman Health Pharmacy LLC as the pharmacy that fills its prescriptions, which most sellers do not
- We found no FDA warning letters issued to Ro
Watch-outs
- Not included in the monthly price: medication
- Confirm it serves your state before you start the intake
Our Verdict
Ivy Rx wins this one, 7.3 to 6.7, above all for coverage in all 50 states, which most sellers will not confirm. Ro undercuts it by $26 a month, so if the monthly bill is what decides it, Ro is the pick. Ro fits better if knowing which pharmacy fills the vial: it names Roman Health Pharmacy LLC is your priority.
Choose Ivy Rx if…
You want coverage in all 50 states, which most sellers will not confirm and an opening price near $175 a month.
Choose Ro if…
You want knowing which pharmacy fills the vial: it names Roman Health Pharmacy LLC and an opening price near $149 a month.
Ready to start? GLP-1 providers we have vetted
Telehealth providers, vetted by us, prescribing GLP-1 online.
Vetted by our editors · no insurance required
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
HealthRX
Compounded semaglutide at $133/month
From $133/mo
Get started →RNK Health
An oral route if you will not self-inject
From $197/mo
Get started →He & She MD
Starting below a standard dose, with microdose tiers
From $99/mo
Get started →Ivy Rx vs Ro: FAQ
Close alternatives to Ivy Rx and Ro
- Ivy Rx vs DudeMeds
- Ivy Rx vs Curve
- Ivy Rx vs FitFlow
- Ivy Rx vs Genesis Health
- Ro vs Amazon One Medical
- Ro vs LillyDirect Foundayo
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.